Sun Pharma
- Healthcare
Sun Pharma Reported a Consolidated Loss of Rs 2227.38 Cr in Q4 of FY22
The company's exceptional items for the fourth quarter of 2021-22 stood at Rs 3,935.75 crore against Rs 672.81 crore in…
Read More » - Corporate
124% Rise in Profit is Marked by Sun Pharma in Q4
Meanwhile, other income for the March quarter is at Rs 111 crore. At the operating level, earnings before interest, tax,…
Read More » - Healthcare
Sun Pharma’s AQCH – Phytopharmaceutical Drug Goes into Phase 2 Clinical Trial for COVID-19 Treatment
Sun Pharma got approval from Drugs Controller General of India (DCGI) for conducting phase two clinical trial in April. The…
Read More » - Healthcare
Sun Pharma Gets DGCI’s Approval for Nafamostat Mesilate Clinical Trials on COVID-19 Patients
In this research, Nafamostat was found to be the most potent drug and was able to inhibit virus entry at…
Read More » - China
Sun Pharma Join Hands with China Medical Systems to Commercialize 7 Generic Products
In June, Sun Pharma -- India's largest drug manufacturer -- had announced a collaboration with the Chinese firm on two…
Read More » - Global
Sun Pharma Launched INFUGEM Injection for Cancer Treatment
“INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the US,” Sun Pharma said in…
Read More » - News
Sensex Jumped Positive 250 Points; Vedanta, Sun Pharma are Top Gainers
As 481 shares advanced, 91 shares declined and 40 shares remained unchanged, the breadth of the markets is positive. The…
Read More »